Send to

Choose Destination
Front Microbiol. 2017 Feb 27;8:293. doi: 10.3389/fmicb.2017.00293. eCollection 2017.

A Novel Antimicrobial Endolysin, LysPA26, against Pseudomonas aeruginosa.

Author information

Department of Microbiology and Immunology, Institutes of Medical Science, Shanghai Jiao Tong University School of Medicine Shanghai, China.
Department of Clinical Medicine, Hangzhou Medical College Hangzhou, China.


The global increase in multidrug resistant (MDR) bacteria has led to phage therapy being refocused upon. A novel endolysin, LysPA26, containing a lysozyme-like domain, was screened against Pseudomonas aeruginosa in this study. It had activity against MDR P. aeruginosa without pretreatment with an outer-membrane permeabilizer. LysPA26 could kill up to 4 log units P. aeruginosa in 30 min. In addition, temperature and pH effect assays revealed that LysPA26 had good stability over a broad range of pH and temperatures. Moreover, LysPA26 could kill other Gram-negative bacteria, such as Klebsiella pneumonia, Acinetobacter baumannii and Escherichia coli, but not Gram-positive bacteria. Furthermore, LysPA26 could eliminate P. aeruginosa in biofilm formation. Our current results show that LysPA26 is a new and promising antimicrobial agent for the combat of Gram-negative pathogens.


LysPA26; Pseudomonas aeruginosa; antimicrobial agent; bacteriophage; endolysin

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center